Fennec Pharmaceuticals (NASDAQ:FENC) just reported results for the second quarter of 2024.
- Fennec Pharmaceuticals reported earnings per share of -20 cents. This was below the analyst estimate for EPS of -3 cents.
- The company reported revenue of $7.26 million.
- This was 34.28% worse than the analyst estimate for revenue of $11.05 million.